Aptose Biosciences Inc. Cash And Cash Equivalents At Carrying Value

• Aptose Biosciences Inc. showed a decrease of -84.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Aptose Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Aptose Biosciences Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 91.2%.
• Historical annual values: Fiscal year 2025: $935.0 thousand | Fiscal year 2024: $6.15 million | Fiscal year 2023: $9.25 million | Fiscal year 2022: $36.97 million | Fiscal year 2021: $39.11 million | Fiscal year 2020: $117.39 million | Fiscal year 2019: $79.84 million | Fiscal year 2018: $15.30 million | Fiscal year 2017: $10.63 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026